Erlanger 1st In Tennessee To Perform AFib Surgery Using New Pulsed Ablation Technology

Erlanger Health has become the first hospital in Tennessee to perform atrial fibrillation (AFib) surgeries using Abbott’s VoltTM Pulsed Field Ablation (PFA) System. The advanced technology delivers precise electrical pulses to disrupt abnormal heart rhythms while minimizing damage to surrounding tissues, a significant improvement over earlier PFA methods. The Volt PFA System features an all-in-one catheter design, allowing simultaneous diagnosis, mapping, and ablation procedures. It also reduces exposure to fluoroscopy and limits red blood cell breakdown, making it safer for patients who previously faced anesthesia barriers. Dr. Harish Manyam, Erlanger’s Chief of Cardiology, conducted the procedure at Erlanger Baroness, adding to his record of medical firsts at the facility. Approximately 12 million Americans over 65 have AFib, with cases expected to double in the next 20 years. Untreated arrhythmias increase stroke and heart attack risks, and the new technology offers hope for patients suffering from shortness of breath, dizziness, and chest pain. Abbott’s Chief Medical Officer, Christopher Piorkowski, noted that pulsed field ablation is a promising advancement for patients with hard-to-treat conditions. Erlanger officials highlighted the system’s ability to overcome limitations of earlier PFA technologies, providing a safer and more effective treatment option. The hospital’s adoption of this innovation positions it as a leader in cardiac care, particularly for patients with complex anatomies or disease.